Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
31 May 2023 - 08:01AM
Business Wire
-- Engineered IL2-Fc Cytokine is Well-tolerated
and Selectively Expands Regulatory T Cells --
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of patients with cancer and autoimmune diseases, today
announced the presentation of results from its Phase 1a
single-ascending dose study of XmAb®564 in healthy volunteers.
XmAb564 is a potency-tuned IL-2-Fc fusion protein, engineered to
selectively activate and expand regulatory T cells (Tregs) for the
potential treatment of patients with autoimmune diseases. Results
will be presented in a poster titled “XmAb564, a Novel
Potency-Tuned IL-2 Fc-Fusion Protein Selectively Expands Regulatory
T Cells: Results from a Single Ascending-Dose Study in Healthy
Adult Volunteers” at the European Congress of Rheumatology (EULAR)
being held May 31 to June 3 in Milan, Italy.
“We have previously presented that a single dose of XmAb564 was
well tolerated in healthy volunteers and generates durable,
dose-dependent and selective expansion of regulatory T cells. The
magnitude and duration of Treg induction may be superior to other
IL-2 candidates evaluated clinically and could potentially support
extended multi-week dosing intervals,” said Bassil Dahiyat, Ph.D.,
president and chief executive officer at Xencor. “We continue to
enroll patients into the Phase 1b, multiple-ascending dose study in
patients with atopic dermatitis and psoriasis, and we anticipate
completing dose escalation in psoriasis cohorts in early 2024.”
The poster is now available under "Events & Presentations"
in the Investors section of the Company's website located at
www.xencor.com.
About XmAb®564 (IL-2 Fc)
XmAb®564 is a wholly owned, monovalent, potency-tuned IL-2-Fc
fusion protein, engineered to selectively activate and expand Tregs
for the potential treatment of patients with autoimmune diseases.
XmAb564 is engineered with reduced binding affinity for IL-2’s beta
receptor (IL-2Rβ, CD122) and increased binding affinity for its
alpha receptor (IL-2Rα, CD25). Xencor’s XmAb Bispecific Fc Domain
additionally provides a stable protein scaffold and improves
XmAb564’s pharmacologic properties, and Xencor’s Xtend™ Fc
technology enhances its circulating half-life.
As presented in November 2022, the Phase 1a study of XmAb564
demonstrated that a single dose of XmAb564 in healthy volunteers
was well-tolerated, promoted the selective and sustained expansion
of Tregs and exhibited a favorable pharmacokinetic profile.
Xencor is conducting a randomized, double-blind,
placebo-controlled, multiple-ascending dose Phase 1b clinical study
to evaluate the safety and tolerability of XmAb564, administered
subcutaneously in patients with atopic dermatitis and
psoriasis.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
proteins structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to, statements regarding presentations of clinical
data, the timing of clinical trials, the quotations from Xencor's
president and chief executive officer, and other statements that
are not purely statements of historical fact. Such statements are
made on the basis of the current beliefs, expectations, and
assumptions of the management of Xencor and are subject to
significant known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
and the timing of events to be materially different from those
implied by such statements, and therefore these statements should
not be read as guarantees of future performance or results. Such
risks include, without limitation, the risks associated with the
process of discovering, developing, manufacturing and
commercializing drugs that are safe and effective for use as human
therapeutics and other risks, including the ability of publicly
disclosed preliminary clinical trial data to support continued
clinical development and regulatory approval for specific
treatments, in each case as described in Xencor's public securities
filings. For a discussion of these and other factors, please refer
to Xencor's annual report on Form 10-K for the year ended December
31, 2022, as well as Xencor's subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, as amended to date. All forward-looking statements are
qualified in their entirety by this cautionary statement and Xencor
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005691/en/
For Investors: Charles Liles cliles@xencor.com 626-737-8118
For Media: Jason I. Spark Evoke Canale
jason.spark@evokegroup.com 619-849-6005
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2024 to Mar 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2023 to Mar 2024